Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Equity Average (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Equity Average for 2 consecutive years, with $61.1 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 55.48% to $61.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.1 million through Dec 2025, down 55.48% year-over-year, with the annual reading at $87.1 million for FY2025, N/A changed from the prior year.
  • Equity Average for Q4 2025 was $61.1 million at Pyxis Oncology, down from $78.2 million in the prior quarter.
  • The five-year high for Equity Average was $177.0 million in Q2 2024, with the low at $61.1 million in Q4 2025.